Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers

Article activity feed

1. Version published to 10.3390/vaccines10030392

   Mar 3, 2022
2. 

   ScreenIT

   Oct 14, 2021

   SciScore for 10.1101/2021.10.07.21264657: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: The study was approved by the local Institutional Review Board (Ref.:26022021-CN-1e-CI) and conducted per The Code of Ethics of the World Medical Association (Declaration of Helsinki) for human experiments. Consent: Due to the prospective nature of the study, every patient had to sign an informed consent form to participate.
   Sex as a biological variable	The inclusion criteria were: individuals of both genders, between the ages of 18 and 100 years, who had signed up the informed consent form and planned to conclude the immunization regimen of any vaccine given by the Mexican National Health System in compliance with the current immunization regimens.
   Randomization	not detected.
   Blinding	not …

   SciScore for 10.1101/2021.10.07.21264657: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: The study was approved by the local Institutional Review Board (Ref.:26022021-CN-1e-CI) and conducted per The Code of Ethics of the World Medical Association (Declaration of Helsinki) for human experiments. Consent: Due to the prospective nature of the study, every patient had to sign an informed consent form to participate.
   Sex as a biological variable	The inclusion criteria were: individuals of both genders, between the ages of 18 and 100 years, who had signed up the informed consent form and planned to conclude the immunization regimen of any vaccine given by the Mexican National Health System in compliance with the current immunization regimens.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   After explaining the study to each patient, emphasizing the follow-up along an entire year through SARS-CoV-2 specific IgG antibodies measurement samples, all participants provided written informed consent.	SARS-CoV-2 specific IgG suggested: None
   Therefore, after 21-28 days of receiving prime-boost vaccination, the research team contacted the participants to take the second plasma sample for IgG antibodies measurement.	IgG suggested: None
   After completing the vaccine regimen, the follow-up questionnaires on the fourth, fifth and sixth IgG antibody samples asked about any suspicious or confirmed SARS-COV-2 infections.	sixth IgG suggested: None
   It used chemiluminescence immunoassay (CLIA) technology to determine the amount of specific anti-S1 and anti-S2 IgG antibodies against SARS-CoV-2 in plasma samples.	anti-S1 suggested: None anti-S2 IgG suggested: None
   The analyzed biochemical variables were SARS-CoV-2 quantitative antibodies from the basal sample (S1), 21-28 days post-Ad5-nCoV (S2), three-month follow-up after immunization (S3), and 21-28 days post-first BNT-boost (S4).	S3 suggested: None S4 suggested: None
   Software and Algorithms
   Sentences	Resources
   The statistical program used was SPSS, version 2.	SPSS suggested: (SPSS, RRID:SCR_002865)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   A limitation of this investigation is the sample size. So further prospective studies must recruit a more significant sample. Another limitation was the time between both vaccines. It could have more relevance to justify the time lapses, but it was established according to the patients’ access to another vaccine.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.10.07.21264657 on medRxiv

   Oct 11, 2021